Editorial Comment

Affiliations

¹ Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.
² Department of Urology, University of Washington, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.

Editorial

Roman Gulati et al. J Urol. 2022 Nov.

. 2022 Nov;208(5):1027.

doi: 10.1097/JU.0000000000002835.04. Epub 2022 Sep 6.

¹ Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.
² Department of Urology, University of Washington, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.

No abstract available

Comment on

Prostate Specific Antigen and Biopsy Contamination in the Göteborg-1 Randomized, Population-Based, Prostate Cancer Screening Trial.
Stinesen Kollberg K, Holmberg E, Josefsson A, Hugosson J, Arnsrud Godtman R. Stinesen Kollberg K, et al. J Urol. 2022 Nov;208(5):1018-1027. doi: 10.1097/JU.0000000000002835. Epub 2022 Jun 30. J Urol. 2022. PMID: 35771961 Clinical Trial.

1. Hugosson J, Roobol MJ, Mansson M, et al. A 16-yrfollow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol. 2019;76(1):43–51. - PMC - PubMed
1. Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Goteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015;68(3):354–60. - PubMed
1. Andriole GL. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst.2012;104(2):125–132 - PMC - PubMed